UCLA School of Nursing Selects QuantRx PadKit® Collection System for Grant Funded Cervical Cancer Study
17 February 2010 - 12:22AM
Business Wire
QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader
in the development and commercialization of innovative diagnostic
products based on its patented technology platforms for the
worldwide point-of-care healthcare industry, today announced that
its proprietary PadKit has been selected as the sample collection
system by the UCLA School of Nursing for a comparative cytology
study of cervical cancer. Led by UCLA School of Nursing Associate
Professor Dr. Dorothy Wiley, the study is funded by an initial
grant from the UCLA School of Nursing and intended to identify a
low cost diagnostic solution for cervical cancer screening in
resource-poor areas.
The need for novel diagnostic tools in the fight against
cervical cancer is vital. Although effective treatment is available
for this cancer in the early-stage, the healthcare community is
challenged in finding a low cost method for making a diagnosis of
cervical cancer. The combination of early diagnosis and treatment
are ideally suited for reducing overall health-care costs, as later
stage diagnosis and treatment is both costly and results in higher
mortality. The World Health Organization states that cervical
cancer is the second biggest cause of female cancer mortality
worldwide with 288,000 deaths yearly. About 510,000 cases of
cervical cancer are reported each year with nearly 80% in
developing countries. Despite broader access to healthcare services
in the U.S., cervical cancer remains a major threat to the female
population in this country. These statistics reveal a growing and
global need for improved cervical cancer screening, particularly in
less developed nations with inferior healthcare resources.
“We are thrilled to work with QuantRx in testing their
Padkit intralabial pad, which we hope will improve access
to cervical cancer screening in high-risk populations,” said
Dr. Dorothy Wiley, Associate Professor at the UCLA
School of Nursing. “Our research focuses on cervical cancer, and
unfortunately many women cannot afford to be regularly
screened. Our goal is to demonstrate that Padkit can be used for
Pap test self-collection, especially in resource-poor areas
with sparse medical facilities. The Padkit is a low-cost
and simple method that we believe can meet this need.”
Dr. William Fleming, QuantRx Chief Scientific Officer and
President of its Diagnostics Group, added, “This effort will help
validate the scientific research, product development and patient
studies previously undertaken and funded solely by QuantRx. The
synergy of the prestigious UCLA School of Nursing and our
experience at obtaining in vitro diagnostics with demonstrable
diagnostic value has the prospect of resulting in a product used in
the fight against cervical cancer that will both reduce the cost of
treatment and affordably bring new healthcare applications to
market.”
About QuantRx Biomedical
(www.quantrx.com)
QuantRx Biomedical Corporation (OTCBB: QTXB) is focused on the
development and commercialization of innovative products for
advanced diagnosis of serious disease and health conditions. With
synergistic expertise in the discovery of diagnostic platforms
leveraging a vast portfolio of intellectual property, QuantRx’s
mission is to introduce products for use by medical professionals,
institutions, and consumers that deliver more accurate, reliable,
and faster diagnoses which result in improved patient care and a
reduction in overall healthcare costs.
The QuantRx strategy targets significant market opportunities
estimated to be in excess of $5 billion worldwide. The Company's
technology portfolio, with more than three dozen patents, patents
pending and licensed patents, includes: (1) RapidSense®
point-of-care testing products based on QuantRx core intellectual
property related to lateral flow techniques for the consumer and
healthcare professional markets (QN Diagnostics); (2) PAD
technology for over-the-counter applications, and the diagnosis and
treatment of women's health concerns and other medical needs, and
(3) significant investments in: (a) genome-based diagnostic chips
for the laboratory and healthcare professional markets; and (b)
molecular imaging agents for positron emission tomography (PET) and
fluorescence imaging, with initial application in cardiovascular
disease, addressing significant unmet medical needs by providing
clinicians with important tools for early discovery and
assessment.
This release may contain forward-looking statements within the
meaning of the federal securities laws. Such forward-looking
statements reflect, among other things, management's current
expectations, management's current plans and strategies, and
anticipated financial results, all of which are subject to known
and unknown risks, uncertainties and factors that may cause our
actual results to differ materially from those expressed or implied
by these forward-looking statements. Many of these risks are beyond
our ability to control or predict including; general economic
conditions, the Company’s need for additional funds, the early
state of the products the Company is developing, uncertainties
relating to clinical trials and regulatory reviews, competition and
dependence on collaborative partners, the Company's ability to
avoid infringement of the patent rights of others, and the
Company's ability to obtain adequate patent protection and to
enforce these rights. Because of these risks, uncertainties and
assumptions, you should not place undue reliance on these
forward-looking statements. Furthermore, forward-looking statements
speak only as of the date they are made. QuantRx does not undertake
any obligation to update or review any such forward-looking
information, whether as a result of new information, future events
or otherwise.
QuantRx Biomedical (CE) (USOTC:QTXB)
Historical Stock Chart
From Sep 2024 to Oct 2024
QuantRx Biomedical (CE) (USOTC:QTXB)
Historical Stock Chart
From Oct 2023 to Oct 2024